Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Sells Shares Under 10b5-1 Plan

Christopher Gibson, CEO of Recursion Pharmaceuticals, sold 138,574 shares of Class A Common Stock at $6.04 per share on March 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 27, 2025, Christopher Gibson, the CEO of Recursion Pharmaceuticals, sold 138,574 shares of Class A Common Stock at a price of $6.04 per share.
• The transaction was executed under a Rule 10b5-1 trading plan adopted on December 19, 2024.
• Following the transaction, Gibson directly owns 1,117,450 shares of Class A Common Stock.
• Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
• He holds options to purchase additional shares of Class A Common Stock at various exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider transactions are common and closely monitored, especially in publicly traded companies like Recursion Pharmaceuticals. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• Comparing Christopher Gibson's transactions to other pharmaceutical CEOs' trading activity would require analyzing similar Form 4 filings.
• Generally, insider sales are not inherently negative, but large or frequent sales can sometimes raise concerns among investors.
• The use of a pre-planned 10b5-1 trading plan is a common practice among executives to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates potential concerns.

Key Dates

Keywords

Form 4, Recursion Pharmaceuticals, Christopher Gibson, RXRX, insider trading, Rule 10b5-1, stock sale, CEO